

PRESSURE BIOSCIENCES INC.

14 Norfolk Avenue
South Easton, MA 02375
(T) 508-230-1828
(F) 508-230-1829
info@pressurebiosciences.com

Mr. Richard T. Schumacher, CEO, President
Dr. Edmund Y. Ting, SVP of Engineering
Dr. Alexander V. Lazarev, Chief Science Officer
Mr. Daniel J. Shea, CPA, Senior Advisor - Finance
Dr. Nate Lawrence, Senior Advisor - Operations

STOCK OVERVIEW

Symbol:	PBIO	Recent Close:	\$1.81 (as of 9/12/20)
Exchange:	OTCQB	52-Week Range:	\$0.60 - \$4.49
Shares OS ¹ :	3.2M (13M FD)	Market Capitalization ² :	\$5.8M (\$24M FD)
Float:	~2.5M	Fiscal Year End:	December 31
Revenue (FY2019):	\$1.8M	Transfer Agent:	Computershare

COMPANY OVERVIEW

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences and other industries. Our products/services are based on three patented, pressure-enhanced platforms: (i) Pressure Cycling Technology ("PCT"), (ii) BaroFold Technology ("BaroFold"), and (iii) Ultra Shear Technology ("UST").

The PCT Platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction). Our primary focus is in making our recently released, GMP-compliant, next generation PCT-based Barocycler EXTREME instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization, and quality control of biotherapeutic drugs. The PCT Platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. We currently have over 300 PCT instrument systems placed in approximately 200 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are over 120 independent publications highlighting the advantages of using the PCT Platform in scientific research studies, many from worldwide key opinion leaders. The PCT Platform is offered through the Company's Research Products & Services Group.

The BaroFold Platform can be used to significantly impact and improve the quality of protein therapeutics. It employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies. The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy and safety for both new-drug entities and biosimilar products. The BaroFold Platform can help companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. It is scalable and practical for standard manufacturing processes. This unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein therapeutics and lower the cost of existing formulations. Research and manufacturing licenses are available.

The UST Platform is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge. UST has been shown to turn hydrophobic extracts into stable, water-soluble formulations on a small, laboratory scale. The UST Platform offers the potential to produce stable nanoemulsions of oil-like products in water. Such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making CBD-enriched plant oil water soluble. We believe that UST has the potential to play a significant role in a number of commercially important areas, including (i) the creation of stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being developed for commercialization.

1. Shares Outstanding (as of June 30, 2020) – includes approximately 3.2M common shares and 9.8M common share equivalents from Preferred Stock Series D, G, H, J, K, and AA on an as-converted basis.
2. Fully Diluted Market Capitalization is calculated using Common Stock OS and Common Equivalent Shares OS on a Fully Diluted basis.

INVESTMENT HIGHLIGHTS

- Pending Acquisition of Cannaworx, Inc. and SkinScience Labs (Announced April 29/30, 2020)
 - Planned Name Change to Availa Bio Following Merger
 - Jim Morrison (ex-President L'Oreal U.S.) Announced as In-Coming CEO of Availa Post Merger
 - PBI has Proven Core Technology with Multiple Applications (Over 300 Pressure Systems Installed Globally)
 - PBI has Three Novel, Enabling, Patented & Proprietary Pressure-based Platforms: PCT, BaroFold, & UST
 - PCT Platform Breaks Through Bottlenecks to Enable/Accelerate Discovery & QC in Drug Development
 - BaroFold Platform Impacts/Improves Protein Drug Therapeutics through Disaggregation and Refolding
 - UST Platform Makes Highly Stable Nanoemulsions for Multiple Applications, e.g., CBD & Cosmetics Products
 - Significant Worldwide Market Opportunities: PCT (BioPharma \$526B); BaroFold (Drug Processing \$44B); UST (CBD \$44B; Cosmetics \$805B; BioPharma Drug Delivery \$900B; Food and Beverages \$5.65T)
-

RECENT & KEY ANNOUNCEMENTS

- **August 12, 2020:** PBI awarded pivotal U.S. patent for novel, high pressure enhanced consumable device
 - June 20: PBI and Leica Microsystems sign worldwide co-marketing alliance: combination of proprietary technologies expected to accelerate cancer R&D with innovative tumor processing workflow
 - June 11: \$3.5 million initial order for FDA-registered premium hand sanitizer catapults SkinScience Labs, a pending accretive acquisition of PBI, into the multi-billion dollar hand sanitizer market
 - June 4: PBI announces first manufacturing build completely sold out for revolutionary UST System for processing hemp-derived cannabinoid oil into stable, water-soluble nanoemulsions
 - May 28: PBI pending merger partner Cannaworx, Inc. announces launch (mid-July 2020) of novel, FDA-registered immune booster
 - May 19: PBI pending merger partner Cannaworx, Inc. announces Letter of Intent to Acquire Five Leaf Labs, delivering major expansion of sales and distribution network
 - May 14: PBI announces launch of FDA-registered hand sanitizer as first product developed through pending merger partners
 - May 7: Former L'Oreal President Jim Morrison, one of the top brand strategists in the personal care space worldwide, appointed as CEO to lead Availa Bio upon merger completion
 - May 5: PBI announces plans to change name to Availa Bio following completion of the Cannaworx and SkinScience Labs merger
 - April 30: PBI announces plans to acquire SkinScience Labs and their profitable and award-winning Dr. Denese Skin Care and Anti-Aging Lines
 - April 29: PBI announces plans to acquire Cannaworx, Inc. and their portfolio of innovative consumer products
 - April 16: PBI and RedShiftBio demonstrate potential of combining proprietary technologies to enable new tool for development and production of biotherapeutics
 - March 12: PBI announces that it is nearing a complete sellout on its pre-launch offering of game-changing UST Platform for processing CBD Oil into water-soluble nanoemulsions.
 - February 27: PBI launches new era in preparation of water-soluble nanoemulsions for CBD and other valuable oils with opening of UST Demonstration Laboratory.
 - January 30: PBI announced acceleration of UST Platform rollout for water-soluble CBD with planned release of additional BaroShear product – a benchtop, R&D scale, BaroShear "Mini" instrument.
 - January 24: PBI announced significant new order and near sellout on revolutionary nanoemulsification system for water-soluble CBD oil. Company said that additional orders are expected shortly.
 - January 17: PBI reported the Company's UST Platform was featured in a leading North American Cannabis Magazine and that the article highlighted the potential of the UST Platform to play a significant role in multiple billion-dollar markets, such as CBD, nutraceuticals, cosmetics, biopharmaceuticals, and food/beverage.
 - January 9, 2020: PBI reported that the number of published scientific papers in 2019 citing the advantages of the Company's PCT Platform remained strong, with over 20 journal articles for the second straight year
 - **October 4, 2019:** Zacks Small Cap Research Initiated Coverage on PBI.
 - October 1: PBI's proprietary PCT Platform said to fill pivotal role for tumor analyses in novel workflow presented at leading global gynecological cancer meeting. Nationally acclaimed scientists said the analysis of cancer tissue proteins from their novel workflow could lead to improved clinical management of gynecologic cancers.
 - September 26: PBI's PCT Platform was featured in 10 separate presentations at a major international science conference in Australia, by scientists from 17 research institutions worldwide. The presentations highlighted novel applications for the PCT Platform in cancer research and diagnostics.
 - September 10: PBI's PCT platform was identified by two prestigious research centers as pivotal for cancer biomarker discovery and for potential clinical diagnostics in studies using preserved (i.e., formalin-fixed paraffin-embedded, or FFPE) cancer biopsy tissue samples.
 - June 27: PBI enters the CBD market with novel process to make high quality, water-soluble CBD Oil.
-

BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Mr. Kevin A. Pollack, Esq.
- Mr. Vito Mangiardi
- Dr. Mickey Urdea
- Mr. Richard T. Schumacher

9/12/2020